Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology.
cancer
hepatitis
immune-related adverse event
immunotherapy
liver
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
29
03
2022
accepted:
06
06
2022
entrez:
18
7
2022
pubmed:
19
7
2022
medline:
20
7
2022
Statut:
epublish
Résumé
Immune checkpoint inhibitors (ICI) are being increasingly used to successfully treat several types of cancer. However, due to their mode of action, these treatments are associated with several immune-related adverse events (irAEs), including immune-mediated autoimmune-like hepatitis in 5 to 10% of cases. The specific immune mechanism responsible for the development of immune-mediated liver injury caused by immune checkpoint inhibitors (ILICI) is currently unknown. This review summarizes the current knowledge on hepatic irAEs during cancer immunotherapy. It also addresses the clinical management of ILICI and how it is becoming an increasingly important clinical issue. Clinical, histological, and laboratory features of autoimmune hepatitis (AIH) and ILICI are compared, and their shared and distinctive traits are discussed in an effort to better understand the development of hepatic irAEs. Finally, based on the current knowledge of liver immunology and AIH pathogenesis, we propose a series of events that could trigger the observed liver injury in ICI-treated patients. This model could be useful in the design of future studies aiming to identify the specific immune mechanism(s) at play in ILICI and improve immune checkpoint inhibitor cancer immunotherapy.
Identifiants
pubmed: 35844534
doi: 10.3389/fimmu.2022.907591
pmc: PMC9280269
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
907591Informations de copyright
Copyright © 2022 Hercun, Vincent, Bilodeau and Lapierre.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet Oncol. 2015 Apr;16(4):375-84
pubmed: 25795410
Am J Surg Pathol. 2015 Aug;39(8):1075-84
pubmed: 26034866
J Clin Invest. 2018 Feb 1;128(2):715-720
pubmed: 29309048
Mod Pathol. 2018 Jun;31(6):965-973
pubmed: 29403081
Cancer Immunol Immunother. 2018 Apr;67(4):563-573
pubmed: 29289977
Frontline Gastroenterol. 2019 Oct;10(4):364-371
pubmed: 31656561
Immunol Rev. 2000 Apr;174:47-62
pubmed: 10807506
Chem Res Toxicol. 2021 Mar 15;34(3):849-856
pubmed: 33617238
Dig Dis Sci. 2012 Aug;57(8):2233-40
pubmed: 22434096
Mod Pathol. 2021 Feb;34(2):426-437
pubmed: 32884128
Chem Res Toxicol. 2015 Dec 21;28(12):2287-91
pubmed: 26529122
Semin Cancer Biol. 2020 Aug;64:29-35
pubmed: 30716481
J Clin Oncol. 2011 Mar 20;29(9):e237-40
pubmed: 21220617
PLoS One. 2019 May 21;14(5):e0217276
pubmed: 31112568
J Autoimmun. 2020 Nov;114:102514
pubmed: 32768244
Hepatology. 2022 Mar;75(3):531-540
pubmed: 34709662
Nat Rev Immunol. 2002 Feb;2(2):85-95
pubmed: 11910899
J Immunother Cancer. 2020 Nov;8(2):
pubmed: 33144335
Immunity. 2005 Aug;23(2):153-63
pubmed: 16111634
Intern Med. 2018 Jun 15;57(12):1789-1792
pubmed: 29434164
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Lancet Oncol. 2018 Jul;19(7):940-952
pubmed: 29875066
Aliment Pharmacol Ther. 2019 Oct;50(7):800-808
pubmed: 31309615
Am J Pathol. 2006 Apr;168(4):1169-78; quiz 1404-5
pubmed: 16565492
J Clin Invest. 2004 Sep;114(5):701-12
pubmed: 15343389
Eur J Cancer. 2018 Mar;91:21-29
pubmed: 29331748
Am J Clin Oncol. 2016 Feb;39(1):98-106
pubmed: 26558876
J Immunol. 2006 Aug 1;177(3):1689-97
pubmed: 16849478
J Immunol. 2002 Jul 15;169(2):983-92
pubmed: 12097405
Liver Int. 2020 Aug;40(8):1906-1916
pubmed: 32329119
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Melanoma Res. 2013 Feb;23(1):47-54
pubmed: 23262440
Clin Gastroenterol Hepatol. 2022 Apr 26;:
pubmed: 35487453
Invest New Drugs. 2013 Aug;31(4):1071-7
pubmed: 23408334
Hepatology. 2015 Apr;61(4):1332-42
pubmed: 25283142
J Clin Invest. 1997 Jun 1;99(11):2782-90
pubmed: 9169509
J Clin Oncol. 2017 Mar;35(7):785-792
pubmed: 28068177
J Immunother Cancer. 2019 Feb 18;7(1):47
pubmed: 30777137
J Clin Oncol. 2014 Apr 1;32(10):1020-30
pubmed: 24590637
J Clin Oncol. 2018 Oct 1;36(28):2872-2878
pubmed: 30125216
J Immunol. 2001 May 1;166(9):5430-8
pubmed: 11313380
Nat Rev Immunol. 2003 Jan;3(1):51-62
pubmed: 12511875
Blood. 2000 Feb 15;95(4):1362-9
pubmed: 10666212
Ann Oncol. 2017 Feb 1;28(2):368-376
pubmed: 27687304
J Immunother Cancer. 2017 Nov 21;5(1):93
pubmed: 29157287
Nat Rev Immunol. 2010 Nov;10(11):753-66
pubmed: 20972472
Transl Res. 2007 Mar;149(3):107-13
pubmed: 17320796
Cytokine Growth Factor Rev. 2011 Feb;22(1):35-43
pubmed: 21334249
J Hepatol. 2018 Dec;69(6):1396-1397
pubmed: 30292476
J Clin Oncol. 2021 Dec 20;39(36):4073-4126
pubmed: 34724392
Cancer. 2018 Sep 15;124(18):3706-3714
pubmed: 29975414
J Immunol. 2004 Aug 15;173(4):2402-9
pubmed: 15294953
J Immunol. 1999 Sep 15;163(6):3202-10
pubmed: 10477588
ESMO Open. 2017 Oct 10;2(4):e000268
pubmed: 29081991
J Hepatol. 2018 Oct;69(4):976-978
pubmed: 30093162
Arthritis Rheumatol. 2019 Dec;71(12):2100-2111
pubmed: 31379105
Chem Res Toxicol. 2015 Aug 17;28(8):1567-73
pubmed: 26154582
JAMA Oncol. 2018 Dec 1;4(12):1721-1728
pubmed: 30242316
Oncologist. 2018 Sep;23(9):991-997
pubmed: 29853659
EBioMedicine. 2020 Dec;62:103040
pubmed: 33166791
J Clin Rheumatol. 2022 Mar 1;28(2):e498-e505
pubmed: 34371516
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Ann Intern Med. 2018 Jan 16;168(2):121-130
pubmed: 29297009
N Engl J Med. 2015 May 21;372(21):2006-17
pubmed: 25891304
Gastroenterol Res Pract. 2012;2012:642923
pubmed: 22474447
Cancer Immunol Immunother. 2018 May;67(5):825-834
pubmed: 29487980
Can J Gastroenterol Hepatol. 2017;2017:2896809
pubmed: 28804705
Minerva Med. 2008 Dec;99(6):595-604
pubmed: 19034257
J Clin Oncol. 2021 Sep 20;39(27):2991-3001
pubmed: 34292792
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
JAMA Oncol. 2020 Nov 01;6(11):e204564
pubmed: 33001135
Lancet Oncol. 2010 Feb;11(2):155-64
pubmed: 20004617
Ann Oncol. 2018 Jan 1;29(1):250-255
pubmed: 29045547
Acta Pharm Sin B. 2021 Dec;11(12):3727-3739
pubmed: 35024302
J Cancer Res Clin Oncol. 2021 Jun;147(6):1747-1756
pubmed: 33222015
Immunity. 1994 Dec;1(9):741-9
pubmed: 7895163
J Hepatol. 2021 Jul;75(1):177-189
pubmed: 33631227
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Hepatology. 2005 Mar;41(3):451-9
pubmed: 15723297
Hepatology. 2006 Feb;43(2 Suppl 1):S54-62
pubmed: 16447271
Ann Oncol. 2017 Mar 1;28(3):671-672
pubmed: 27993797
JHEP Rep. 2020 Aug 11;2(6):100170
pubmed: 33205034
J Hepatol. 2018 Jun;68(6):1181-1190
pubmed: 29427729
N Engl J Med. 2011 Jun 30;364(26):2517-26
pubmed: 21639810
J Hepatol. 2017 Mar;66(3):657-659
pubmed: 27908801
Clin Ther. 2019 Jan;41(1):59-67
pubmed: 30528047
Cell Death Dis. 2018 Sep 5;9(9):909
pubmed: 30185788
Front Oncol. 2021 Apr 21;11:650292
pubmed: 33968750
Eur J Cancer. 2019 Dec;123:112-115
pubmed: 31678768
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Int J Cancer. 2017 Sep 1;141(5):1018-1028
pubmed: 28263392
J Hepatol. 2018 Aug;69(2):548-550
pubmed: 29747956
Med Sci (Paris). 2007 Nov;23(11):985-90
pubmed: 18021712
J Clin Oncol. 2017 Dec 1;35(34):3851-3858
pubmed: 28678668
Lancet Oncol. 2015 Mar;16(3):257-65
pubmed: 25704439
Nat Rev Dis Primers. 2020 May 7;6(1):38
pubmed: 32382051
J Immunol. 2004 May 1;172(9):5222-9
pubmed: 15100260
Hepatology. 2020 Dec;72(6):2235-2238
pubmed: 32484945
Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142
pubmed: 28881921
J Immunother Cancer. 2019 Aug 22;7(1):226
pubmed: 31439050